Trial Profile
A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia; Cancer; Glioma; Myelodysplastic syndromes; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 26 Feb 2024 Planned End Date changed from 25 Oct 2024 to 24 Oct 2025.
- 01 Mar 2023 Status changed from active, no longer recruiting to suspended according to results published in the Journal of Cancer Research and Clinical Oncology
- 01 Mar 2023 Results (n=41) published in the Journal of Cancer Research and Clinical Oncology